In October, Antibody Solutions was proud to take part in the annual Festival of Biologics (FoB) in Basel, Switzerland. While our team is no stranger to international conferences, this was our first since the start of the SARS-Cov-2 pandemic in early 2020. So it was a special treat to spend three days catching up with colleagues from around the world.
The Basel conference drew 2,500+ visitors from more than 40 countries, and addressed a range of concentrations across the biologics space. Attendance included a broad mix of vendors, researchers, and investors. We contributed a poster, Pathways to Antibody Discovery Using the CellestiveTM Platform, and enjoyed entertaining colleagues (both established and prospective clients) who stopped by our booth to discuss our services. Three of our other highlights included talks by Dr. Silvia Crescioli of King's College, London, on “Trends in commercial development of antibody therapeutics”; Rinse Klooster of Merus on “Delivering unique functionality in bispecific antibodies;” and technology updates from our friends at OmniAb and Atum.
We’re looking forward to attending April’s FoB in San Diego, but you certainly don’t have to wait until then to share your latest challenges and opportunities with us. If you’re in need of critical antibody discovery services, or if you just want more information about what we can offer through our Cellestive platform, drop us a line and we can get started.
The Festival of Biologics took place in Hall 1 of Messe Basel, an especially impressive structure both inside and out.
Antibody Solutions’ corner booth, on its way to being ready for showtime!
Antibody Solutions’ booth was close to one of several “Theatres” set up around FoB. As with any major convention like this, a range of fascinating talks were held both on the main stage and in spots like this.
We were happy to be able to provide refreshments to those who stopped by to chat with us. Cheers to all FoB Basel attendees – see you in San Diego!
Author of more than 40 publications, John’s current research interests include new technologies for improving therapeutic antibody discovery, properties of next-generation antibody-like molecules, and best practices for critical reagents used in biologics development.